PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Linzess Off to Solid Start, Astellas Eyes Big Indication Addition
July 26, 2017
- Lenvatinib Filed for HCC in US and EU after Japan Submission
July 26, 2017
- AZ Japan to Work to Create “Frameworks for Success”: Commercial Excellence Head
July 26, 2017
- Sumitomo Dainippon to Invest up to US$10 Million in Investment Partnership
July 26, 2017
- Janssen to Sell Tapenta License to Mundipharma in Japan
July 25, 2017
- Positive Top-Line Data Out for Shionogi’s Sakigake-Designated Flu Med
July 25, 2017
- Boehringer Japan, Kyoto Univ. Seal 2-Year COPD Pact
July 25, 2017
- Novartis Wants to Deliver CAR-T Therapy to Japanese Patients ASAP: Exec
July 25, 2017
- Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief
July 25, 2017
- (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 25, 2017
- Ono Focuses on Combination Therapy of Opdivo with Chemotherapies; Development of Small-Molecule Drugs also Underway
July 25, 2017
- Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 24, 2017
- Gilteritinib Earns US Orphan Status for AML: Astellas
July 24, 2017
- Hemophilia A Treatment Emicizumab Filed in Japan: Chugai
July 24, 2017
- Takeda, Schrödinger Link Up on Drug Discovery
July 24, 2017
- Asahi Kasei Pharma to Expand Lineup in Orthopedic Field, Boost Osteoporosis Market Share through Once-Yearly Formulation of Reclast
July 24, 2017
- AZ Japan Facing Civil Lawsuit over Demotions, Pay Cuts
July 21, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Takecab Most Promoted Drug for Hospital Doctors for 7th Month: Anterio
July 21, 2017
- NanoCarrier’s Micellar Nanoparticle Drug Gets FDA Orphan Status
July 20, 2017
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…